Drug Type CAR-T |
Synonyms |
Target- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization TeraImmune, Inc.Startup |
Active Organization- |
Inactive Organization TeraImmune, Inc.Startup |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Preclinical | US | TeraImmune, Inc.Startup | 10 Feb 2022 |